SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Harold Engstrom who wrote (5333)1/4/2002 3:04:41 PM
From: Icebrg  Read Replies (2) | Respond to of 52153
 
Harold,

The BLA was submitted for marketing approval to treat irinotecan-refractory colorectal carcinoma. But if these patients were after all not irinotecan-refractory, it is not possible to say if Erbitux had any effect or not. The positive effects seen might in such a case have been caused by irinotecan alone.

Ice